A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-14

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

NCT06425003

Healthy Volunteer

COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

NCT06849791

Healthy Volunteer

RECRUITING PHASE1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798

Healthy Volunteers

COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

NCT05836506

Healthy Volunteer

COMPLETED PHASE1

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

NCT01053520

Healthy Female Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABBV-932

Participants will receive a single oral dose of ABBV-932 on day 1.

Group Type EXPERIMENTAL

ABBV-932

Intervention Type DRUG

Oral Capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABBV-932

Oral Capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index (BMI) ≥ 18.0 to ≤ 29.9.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
* Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after the study drug administration
* A condition of general good health, based upon the results of a medical history, physical exam

Exclusion Criteria

* Has not participated in another \[14C\] absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq in the period of 12 months prior to screening.
* Use of any medications/products known to alter drug absorption, metabolism, or excretion processes, within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.
* Prior exposure to ABBV-932 or cariprazine within the past 90 days.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes